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Summary 
We have defined the regions of the cytoplasmic domain of the leukocyte integrin lymphocyte 
function-associated antigen 1 (LFA-1) that are required for active binding of its extracellular domain 
to  intercellular  adhesion molecule 1  (ICAM-1).  The NH2-terminal  28  amino acids  in  the 
cytoplasmic domain are dispensable, but a segment of 5 amino acids including three contiguous 
threonines (758-760) and Phe 766 in the COOH-terminal third of the cytoplasmic domain are 
required for binding to ICAM-1. Mutation and phosphoamino acid analysis show that Set 756 
is the major residue phosphorylated in response to phorbol ester. Furthermore, multiple mutations 
demonstrate that serine phosphorylation can be dissociated from phorbol ester-stimulated binding 
of LFA-1 to ICAM-1. The sites we have defined are previously unremarked, are well conserved 
in the ~31, 133, and B7 integrin subunits, and may be of broad importance in regulating adhesiveness 
of integrins. 
1  "lymphocyte function-associated antigen  1 (LFA-1)  is  a 
member of a family of cell-cell adhesion molecules known 
collectively  as the leukocyte integrins. The leukocyte inte- 
grins  have a  common ~3 subunit  (CD18)  and distinct ol 
subunits:  o~L, LFA-1, CDlla;  o~M, Mac-l,  CDllb;  olX, 
p150,95, CDllc. LFA-1 is involved in CTL and NK cell-medi- 
ated cytolysis, antibody-dependent cytotoxicity mediated by 
monocytes and granulocytes, helper T lymphocyte responses 
to antigen presentation, and leukocyte adhesion to endothelial 
cells, fibroblasts, and epithelial cells (1). Two counter-receptors 
for LFA-1, intercellular adhesion molecules 1 and 2 (ICAM-1 
and -2),  have thus far been identified, and recent evidence 
suggests a third (2-5). Interaction with the ICAMs requires 
activation of LFA-1 (6, 7). This activation event can be trig- 
gered by engagement of the TCR complex, or stimulation 
with phorbol esters. Activation results in the ability of LFA- 
1 to bind stably to ICAM-1 without any change in the quan- 
tity of LFA-1 per cell. Since this is measured as cellular binding 
to purified ICAM-1 on a substrate and involves multivalent 
LFA-1/ICAM interactions, it is referred  to as a change in 
avidity; it may reflect conformational changes in the extracel- 
1  Abbreviations used in this paper: ICAM, intercellular adhesion molecule; 
LAD, leukocyte adhesion deficiency;  LFA, lymphocyte function-assodated. 
lular domain of LFA-1. PMA induces a sustained increase in 
LFA-1 avidity, whereas T cell receptor crosslinking induces 
a transient increase in avidity that peaks 10 min after cross- 
linking and declines by 30 min (6). This may provide a mech- 
anism for regulating T ceil adhesion and de-adhesion with 
antigen-presenting and target cells. Pharmacologic studies sug- 
gest that the high avidity state of LFA-1 is stimulated by pro- 
tein kinase C, and inhibited by protein kinase A. By contrast 
to this regulatability,  the ICAMs are constitutively avid for 
LFA-1. 
Although it has been suggested that phosphorylation of 
the B subunit may activate the high avidity state of leukocyte 
integrins (8, 9), this requires further study. The ~  subunit 
of LFA-1 is constitutively phosphorylated, whereas the/3 
subunit is phosphorylated in response to phorbol esters (10), 
correlating with induction of adhesiveness through LFAol 
(6). The findings that the induction of the high avidity state 
of LFA-1 is not due to quantitative changes in density and 
that LFA-1 can go from low to high avidity after  antigen 
receptor crosslinking, return to the low avidity state, and then 
after restimulation with phorbol ester can return to the high 
avidity state all within 40 min (6) suggest that modifications 
of a reversible nature, such as phosphorylation, are good can- 
didates for the regulatory mechanism. Phorbol esters stimu- 
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ol subunits of Mac-l, LFA-1, and p150,95 on neutrophils and 
mononuclear cells, correlating with induction of prolonged 
adhesiveness; the chemoattractant fMLP stimulates more tran- 
sient adhesiveness and has been reported either to induce tran- 
sient phosphorylation (8) or not to stimulate phosphoryla- 
tion (11) of the CD18/3 subunit. The phorbol ester-stimulated 
phosphorylation of the/$ subunit for both LFA-1, Mac-l, 
and p150,95 has been reported to be predominantly on serine 
residues (8, 10). Studies to date have provided correlative rather 
than direct evidence that phosphorylation of the/~ subunit 
regulates adhesiveness.  An alternative interpretation is that 
phosphorylation activates  a distinct protein that promotes 
transition of  LFA-1 to a high avidity state, perhaps by binding 
to a critical region of LFA-1, or that phosphorylation is not 
critical to avidity regulation at all. 
Establishing the contact sites on leukocyte integrins that 
are important to avidity regulation is key to unraveling the 
nature of the covalent modifications or noncovalent interac- 
tions with other molecules that provide the regulatory signals. 
Studies to date have shown that the/3 subunit cytoplasmic 
domain is required (12), but specific sequence motifs within 
the cytoplasmic domain have not been defined. Deletion of 
the cytoplasmic domain of the LFA-1 ~ subunit, but not the 
ot subunit, eliminates binding to ICAM-1 and prevents stim- 
ulation of LFA-1 by PMA. The importance of the/3 subunit 
cytoplasmic domain for integrin function is also suggested 
from cDNA cloning studies that show very strong evolu- 
tionary conservation of the leukocyte integrin fl but not ot 
subunit cytoplasmic domain sequences (reviewed in reference 
12). Although the COOH-terminal five amino acids of the 
subunit were shown to be crucial for retention of the adhe- 
sive properties of LFA-1, other important regions in the cy- 
toplasmic domain were not identified due to the deleterious 
effect of truncating this region on ICAM-1 binding. Similar 
truncation studies on the integrin 31 or VLA subfamily show 
that cytoplasmic domain truncation abolishes ability to localize 
at focal contacts where both the extracellular matrix and the 
cytoskeleton are closely associated with the plasma membrane 
(13-15),  but  that  solubilized truncated receptors  bind  to 
fibronectin (13). In this study, we define a cluster of three 
threonine residues and a single phenylalanine, located in the 
COOH-terminal third of the 3 subunit cytoplasmic domain, 
that are necessary for ligand binding. We demonstrate that 
Set 756 in the/3 subunit cytoplasmic domain is the major 
site phosphorylated in response to PMA, but that phosphory- 
lation of this residue can be dissociated from regulation of 
LFA-1 avidity. 
Materials and Methods 
MonoclonalAntibodies.  All mAbs have  been described  previously. 
W6/32 is a mouse mAb specific  for human HLA-A,B  and was used 
as a control in these studies (16). K1L1/1 is a mAb against ICAM-1 
(2). TS1/22 is a mAb directed against the LFA-1 ce subunit, and 
TS1/18 and R.15.7 are mAbs that recognize the/3 subunit (17, 18). 
Cell Lines and cDNA  Transfection.  COS ceils are SV40-trans- 
formed monkey kidney fibroblasts (19) and were used for transient 
expression of wild-type and mutant LFA-1 molecules. COS cells 
were cotransfected with purified LFA-1 cr and B subunit cDNAs 
contained in the transient expression vector CDM8 (20, 21) as de- 
scribed (22). An EBV-transformed  B lymphoblastoid cell line de- 
rived from a patient with severe  leukocyte  adhesion  deficiency  (LAD) 
(patient 2, SLA) (23) was used to generate stable  cell  lines  expressing 
mutant LFA-1 molecules. B subunit mutants were subcloned into 
the EBV-based vector p205L18a and transfected into the LAD pa- 
tient B lymphoblastoid cells as described (20). An LAD patient 
cell line derived  from patient 2 that expresses the wild-type/3 subunit 
has been described (20). Flow cytometric analysis  was used to quan- 
titate cell surface expression of the transfected COS and LAD B 
lymphoblastoid cells (20). 
Construction of  Mutant 13 Subunits.  ~ subunit mutants were gener- 
ated by oligonucleotide-directed mutagenesis in  CDMS,  using 
second-strand synthesis on uracil-containing templates made in a 
dut-  ung-  mutant host followed by selection against the wild- 
type, uracil-containing template in a dut + ung + host (24). All mu- 
tations were verified by nucleotide sequencing of the region en- 
coding the cytoplasmic domain. 
Purification of lCAM-1 and Binding of Transfected Cells to Purified 
ICAM-I.  ICAM-1  was purified from lysates  of splenocytes  from 
patients with hairy cell leukemia and absorbed to the wells of a 
microtiter plate as described (20). Binding of patient LAD trans- 
fectants to purified, plastic-bound ICAM-1 was performed as de- 
scribed (20). Binding of COS cell transfectants to ICAM-1 was 
as described (20), except that 2  x  104 cells were added to each 
well and incubation was carried out at room temperature for I h. 
Radiolabelin,r Immunoprecipitation, and Electrophoresis.  COS cell 
transfectants and transfected  B lymphoblastoid  cells were harvested 
and washed  four times with phosphate-free  medium (30 mM Hepes, 
pH  7.4, 110  mM glucose, 110  mM NaC1, 5mM KCI,  1 mM 
CaClz, 1 raM MgClz, 2 mg/ml BSA). The cells were resuspended 
in 1 ml phosphate-free medium containing 2 mCi 32p (ICN Bio- 
medical, Costa Mesa, CA) and incubated at 37~  for 2 h. After 
washing once, each cell type was divided into two and either in- 
cubated for 10 min at 37~  with medium alone or with 125 ng/ml 
PMA. Labeled  cells were solubilized in i m120 mM Tris-HC1, pH 
7.4, 250 mM NaC1, 50 mM NaHzPO4, 50 mM NaF, 25 mM 
Na4PzOT, 10 mM iodoacetic acid, 5 mM EDTA, 5 mM EGTA, 
1 mM PMSF, 1 mM Na3VO4, 1%  NP-40, 1 /~g/ml pepstatin, 
1/~g/ml antipain, and 5/~g/ml leupeptin. The extract was cen- 
trifuged at 16,000g for 15 min at 4~  and hemoglobin was added 
to the supernatant to 10 mg/ml. LFA-1 was immunoprecipitated 
with an anti-~  subunit mAb directly conjugated to Sepharose 
(R15.7, a generous gift of  Dr. R. Rothlein, Boehringer-Ingelheim, 
Danbury, CT) for 1 h at 4~  Immunoprecipitates were washed 
twice with lysis  buffer containing I mg/ml hemoglobin, twice with 
50 mM Tris-HC1, pH 8.0, 500 mM NaC1, and once with 20 mM 
Tris-HC1, pH 6.8, then boiled and run on reducing 7.5% SDS-poly- 
acrylamide mini-gels (25). The coomassie-stained  gels were dried 
and autoradiographed  using Kodak  XAR film with Kodak  X-Omatic 
intensifying  screens. Both the coomassie-stained  gels and autoradio- 
graphs were scanned using an Ultroscan XL densitometer (LKB 
Instruments,  Gaithersburg, MD). 
Phosphoamino Acid Analysis.  The B subunit band was excised 
from the dried gel and digested with 10 #g trypsin in 200/zl 50 
mM ammonium bicarbonate overnight at 30~  The superuatant 
was removed and the gel slice lyophilized. The trypsin digestion 
was repeated using 5 #g trypsin in 100/zl 50 mM ammonium bi- 
carbonate for 6 h. The supernatants were pooled and lyophilized. 
The pellet was resuspended  in 300 #16 N HCI and heated to 110~ 
under vacuum for 90 min in an hydrolysis  tube (Pierce Chemical 
Co., Rockford, IL). The hydrolysate  was lyophilized  and resuspended 
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taming 1 #g each of phosphoserine, phosphothreonine,  and phos- 
photyrosine  standards. The sample was spotted on a TLC plate 
('I"-6890; Sigma Chemical Co., St. Louis, MO) and subjected to 
electrophoresis in pH 1.9 buffer at 1,500 V for 45 min using an 
electrophoresis unit (2117; LKB Instruments).  The plate was then 
dried and rewet with pH 3.5 buffer (5% acetic acid, 0.5% pyri- 
dine). After a 90  ~ rotation, the sample was subjected to electropho- 
resis in the second dimension in pH 3.5 buffer at 1,000 V for 35 
min. The plate was then dried and sprayed with 1% ninhydrin to 
reveal the position of the phosphoamino acid standards. The radio- 
labeled phosphoamino acids were visualized by autoradiography as 
above. 
Results 
Identification of Important Amino Acids at the COOH Ter- 
minus of the 3  Subunit.  Mutagenesis  studies have demon- 
strated that the cytoplasmic domain of the LFA-1 3  subunit 
is crucial for regulation of adhesion of LFA-1 to ICAM-1 (12). 
More specifically, these studies have shown that the COOH- 
terminal five amino acids of the 3  subunit are required.  To 
determine which amino acid(s)  in this COOH-terminal re- 
gion were necessary for adhesion  regulation,  a series  of 
subunit  point  mutants  were constructed  (Fig.  1).  The 
subunit point mutants were cotransfected into COS cells with 
the wild-type LFA-1 ot subunit, and their ability to bind to 
ICAM-1 was examined (Fig. 2). AU of these 3 subunit point 
mutants could be expressed on the surface of COS cells to 
essentially the same degree as wild-type LFA-1 (not shown). 
Removal of the COOH-terminal  five amino acids of the 
subunit (mutant BK765") severely diminished ICAM-1 bind- 
ing  as previously demonstrated;  however,  deletion  of the 
COOH-terminal  two amino  acids including  the COOH- 
terminal serine (mutant 3E768") had no effect (Fig. 2). Mu- 
tation of the phenylalanine at position 766 to either an ala- 
nine  or  a leucine  (3F766A  or BF766L)  reduced  ICAM-1 
binding  to the levels observed when  the COOH-terminal 
five amino acids were removed. With the conservative sub- 
stitution of tyrosine for phenylalanine (flF766Y), LFA-1 func- 
tion was retained. Substitution of the remaining amino acids 
in this COOH-terminal five amino acid segment, K765 and 
A767, had no effect on ICAM-1 binding. Thus, a single amino 
acid in this region of the 3  subunit,  F766,  is required for 
LFA-1  function. 
Identification of Other Important Functional  Regions in the 
Subunit Cytoplasmic Domain.  To determine whether there 
are other regions within the 3  subunit cytoplasmic domain 
that  are essential for adhesion  to ICAM-1,  several internal 
deletion mutants were constructed (Fig.  1). These deletion 
mutants,  when cotransfected with  the wild-type LFA-1  ol 
subunit cDNA, were expressed on the surface of COS cells 
to the same level as wild-type LFA-1 (not shown). Deletion 
of either  17 or 28 amino  acids from the NH2 terminus  of 
the 3  subunit cytoplasmic domain had no effect on binding 
of LFA-1 to ICAM-1, demonstrating that the first 28 amino 
acids in the 3  subunit cytoplasmic domain are not required 
for adhesion (Fig. 3). By contrast, removal of the five amino 
acids  between  $756  and  M762  (mutant  3S756AM762) 
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Schematic representation of the wild-type/3 subunit showing 
extracellular, transmembrane (Tm), and cytoplasmic (Cyt) domains, and 
3 subunit point and deletion mutants. The sequence  of the/3 subunit cy- 
toplasmic domain beginning at K724  is shown. Nomendature for the point 
mutations:/3S730A indicates that $730 in the unprocessed/3 subunit has 
been mutated to an alanine. Nomenclature for the deletion mutants: 
3L726A~742 indicates a deletion that joins L726 to K742. 
significantly reduced ICAM-1 binding, indicating that either 
the amino acids in this region were important for adhesion 
or that  the structural  integrity of the cytoplasmic domain 
had been disturbed in this mutant.  Additional mutagenesis 
studies of amino acids in this region (see below) support the 
first hypothesis. 
Functional Analysis of Potential Phosphorylation Sites in the 
Cytoplasmic Domain of  the [3 Subunit.  To determine whether 
direct phosphorylation of the/3 subunit of LFA-1 is respon- 
sible for the LFA-1 avidity change, point mutants to all poten- 
tial phosphorylation  sites in the cytoplasmic domain of the 
/3 subunit were made (Fig.  1). These mutants were first tested 
for their ability to bind to ICAM-1 (Fig. 4), and then their 
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Figure 2.  Binding of COS cells expressing 
LFA-1 with mutations in the COOH-terminal 
five amino acids of the fl subunit to purified 
ICAM-1. Binding was performed in the pres- 
ence of anti-HLA-A,B (control; one-fourth di- 
lution of supernatant, sol/d  bars)  or anti-ICAM-1 
(RR1/1;  one-fourth dilution of supernatant, 
hatched bars; binding was 0 in most cases so 
bars are not visible as denoted by asterisks). Cell 
surface expression of LFA-1 was determined by 
flow cytometry using an anti-LFA-1 cx subunit 
mAb (TS1/22) before each binding assay. Cell 
binding was corrected for the levels of LFA-1 
expressed by the different transfectants. Results 
are expressed as mean _+ SD. This experiment 
is representative  of four independent trials. 
phosphorylation status was determined (see below). The cy- 
toplasmic domain of the/3 subunit contains eight potential 
sites of phosphorylation (Fig.  1), and previous studies have 
suggested that phosphorylation is on serine residues (8, 10). 
Substitution of the four serine residues in the cytoplasmic 
domain individually to amino acids incapable of being phos- 
phorylated had little, if any, effect on ICAM-1 binding (Fig. 
4 A).  In addition,  mutation of the four serine residues in 
combination was not deleterious to ICAM-1 binding and, 
in fact, surface expression and ICAM-1 binding by this mu- 
tant appeared to be marginally enhanced (not shown). Simi- 
larly, mutation of the single tyrosine residue in the/3 subunit 
cytoplasmic domain to a phenylalanine had no influence (Fig. 
4 A). In contrast, alteration of each of the three contiguous 
threonine residues in the/3 subunit cytoplasmic domain (T758, 
T759, T760; Fig. 1), had a significant effect on the adhesive 
capacity of LFA-1 (Fig. 4 B). Mutation of each of the threo- 
nine residues individually resulted in a 50% reduction in LFA-1 
function, and when the three threonines were mutated in 
combination, there was almost complete loss of function (Fig. 
4 B). These results paraUel those seen with the nonfunctional 
deletion mutant flS756AM762 in which all threonine residues 
were deleted (Figs. 1 and 3), and indicate that the three threo- 
nine residues in the/3 subunit cytoplasmic domain are essen- 
tial requirements  for  normal  LFA-1  adhesion. 
Phosphorylation of the LFA-1 fl Subunit.  Phosphorylation 
was initially examined using COS cells transiently expressing 
mutant fl subunits. LFA-1 expressed in COS cells is believed 
to be in a constitutively active state as no stimulation is re- 
quired for adhesion to ICAM-1 and phorbol ester treatment 
has little effect on adhesion (21).  The fl subunit is constitu- 
tively phosphorylated to a low level in COS cells transiently 
expressing wild-type LFA-1, and, in contrast to the lack of 
effect on adhesion, a three- to five-fold increase in phosphory- 
lation of the/3 subunit is observed after treatment with PMA 
(Fig. 5, A  and B). The phosphoamino analysis  of the wild- 
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Figure 3.  Binding of COS cells expressing 
LFA-1 with internal deletions in the fl subunit 
cytoplasmic  domain  to  purified  ICAM-1. 
Binding was performed in the presence of anti- 
HLA-A,B (control) or anti-ICAM-1 (RRI/1) 
and as described in the legend to Fig. 2. 
Binding Sites of Lymphokine Function-associated Antigen 1 A  SO 
B 
40 
~c  30 
111 
o 
O 
~  2o 
10 
60 
50 
40 
ii1 
O  30 
~  20 
10 
WT  ~S730A  ~Y73SF  ~$745A  (3S756C  ~$769A 
WT  ~,T758A  1~'1"759L  ~T760A  J~T758TT/AAA 
￿9  Control 
[]  AntI-ICAM-1 
￿9  Control 
[]  Anti-ICAM-1 
Figure 4.  Effect of mutation of potential 
phosphorylation sites in the cytoplasmic do- 
main of the B subunit on transfected  COS cell 
binding to ICAM-1. (A) Serine and tyrosine 
mutations; (/3) threonine mutations. Binding 
was performed in the presence of anti-HLA- 
A,B (control) or anti-ICAM-1 (RR1/1) as de- 
scribed in Fig. 2. 
type 3  subunit from PMA-stimulated cells established that 
the phosphorylation occurs on serine with a much smaller 
amount of threonine phosphorylation (Fig.  5 C). To deter- 
mine if there was a direct correlation between phosphoryla- 
tion of the LFA-1 B subunit and the change in LFA-1 avidity, 
the phosphorylation status of all B subunit serine, tyrosine, 
and threonine mutants was analyzed. LFA-1 was isolated by 
immunoprecipitation and SDS-PAGE gels were subjected to 
coomassie blue staining and then autoradiography. Both the 
stained gel and the autoradiogram were subjected densitom- 
etry, which confirmed that:  (a) similar but slightly varying 
amounts of mutant and wild-type LFA-1 were precipitated 
(Fig.  5 A);  (b) the ratio of 32p to protein in the ot subunit 
was the same in all precipitates;  and (c) this ratio of 32p to 
protein was the same for the ot subunit with and without 
PMA. Therefore,  to correct for small variations in the efficiency 
of mutant  LFA-1  expression  or  immunoprecipitation,  B 
subunit phosphorylation  is expressed as the percent  of the 
phosphorylation of the oe subunit in the same lane. The elimi- 
nation  of PMA-stimulated  phosphorylation  in the mutant 
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3S756C identifies serine 756 as the major phosphorylation 
site.  Little, if any, of the PMA-stimulated phosphorylation 
could be attributed to the other three potential serine phos- 
phorylation sites (Fig.  5, A  and B) or the potential tyrosine 
phosphorylation site. Analysis of 3 subunit mutants that had 
truncated cytoplasmic domains (Hibbs et al.) and lacked $756 
demonstrated  very little phosphorylation  and no enhance- 
ment with PMA (not shown). Of the three contiguous threo- 
nine residues, mutation of T758 abolished PMA-stimulated 
phosphorylation,  whereas mutation of T759 and T760 had 
little effect (Fig. 5, A and B). The reduction of phosphoryla- 
tion caused by the mutant BT758A could not be accounted 
for by an effect on phosphothreonine;  phosphothreonine is 
present in lower amount than phosphoserine after PMA stim- 
ulation, suggesting that the replacement of threonine to ala- 
nine at 756 affects phosphorylation of the nearby serine 756 
residue.  Further evidence for an effect on phosphorylation 
by T758 was obtained from mutant BT758TT/AAA, in which 
all  three  threonines  had been mutated  in combination.  3 
subunits  immunoprecipitated  from  PMA-treated  cells  ex- Figure 5.  Identification of the phosphory- 
lation sites in the B subunit cytoplasmic do- 
main using COS cells expressing  mutant/3 
subunits.  (,4)  Autoradiograph of 32p-labeled 
LFA-1 immunoprecipitated from  COS  cells 
cotransfected  with  the  wild-type  LFA-lc~ 
subunit and either the wild-type  3 subunit, or 
the designated mutant 3  subunit. Cells were 
either treated with medium alone "-" or with 
125 ng/ml PMA "+" before lysis and immu- 
noprecipitation. Two separate, representative ex- 
periments are shown, each with a wild-type 
control. (B) Scanning  densitometry of the 3 
subunit bands shown in A. ~  subunit phos- 
phorylation is expressed as a percentage of the 
phosphocylation of the ~  subunit in the same 
immunoprecipitate" as described in the text. (C) 
Phosphoamino acid analysis of the B subunit 
immunoprecipitated from COS cells transfected 
with wild-type LFA-1 and treated with PMA. 
pressing this mutant showed baseline levels of phosphoryla- 
tion (not shown). Upstream residues also were important 
for kinase recognition, because a deletion terminating at the 
lysine just NH2 terminal to $756 (L726AK755) abolished 
PMA-stimulated  phosphorylation (Fig.  5, A  and B). 
To examine/3 subunit phosphorylation sites in a more phys- 
iological cell type, each of the phosphorylation  site point mu- 
tants was expressed in an EBV-transformed B lymphoblastoid 
cell line derived from a patient with LAD. This cell line lacks 
expression of LFA-1 due to a single point mutation in the 
extracellular  domain of its ~ subunit, which presumably affects 
ot/3 association (26), and has been used successfully before 
for transfection studies (12, 20). Flow cytometric analysis of 
hygromycin-resistant cell lines transfected with the wild-type 
subunit or the fl subunit point mutants demonstrates that 
expression of LFA-1 c~ and/3 subunits has been reconstituted 
on the surface  of these cells (Fig. 6). Equivalent levels  of LFA-1 
were expressed by the different transfectants. Untransfected 
cells show very low levels of expression of LFA-1 (Fig. 6; 
reference 12). 
Phosphoamino acid analysis of the/3 subunit immunopre- 
cipitated from PMA-stimulated LAD B lymphoblastoid cells 
expressing wild-type LFA-1 demonstrated that the major phos- 
phorylation site occurs on serine and that there is a small 
amount of threonine phosphorylation (Fig.  7 A), corrob- 
orating the results  in COS cells. 
Phosphorylation studies using the LAD patient B lym- 
phoblastoid cells expressing each of the phosphorylation site 
point mutants confirmed the results with the COS cell trans- 
fectants (Fig. 7, B and C)./3 subunits  immunoprecipitated 
from cell lines expressing either ~$756C or 3T758A showed 
a lack of PMA-stimulated  phosphorylation compared with 
subunits  immunoprecipitated from cells expressing wild- 
type LFA-1 or the other six 3  subunit phosphorylation site 
point mutants. The phosphoamino acid analysis  coupled with 
the point mutation phosphorylation studies unequivocally 
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Figure  6.  Cell surface expression of/3 subunit point mutants following 
transfection ofB lymphoblastoid calls derived from an LAD patient (P2). 
The indicated transfectants were stained with either anti-LFA-l~x  subunit 
(TS1/22),  or anti-B subunit mAbs (TS1/18), or a nonbinding negative 
control mAb (x63). 
demonstrate Ser 756 is phosphorylated in response to PMA. 
The studies further demonstrate that phosphorylation of Ser 
756 is affected by mutation of Thr 758. 
Lack of Correlation between 8 Subunit Phosphorylation and En- 
hancement of  LFA-I Avidity.  In an attempt to directly corre- 
late 8 subunit phosphorylation  with the LFA-1 avidity change, 
transfected EBV-transformed  B  lymphoblastoid cells were 
tested for their ability to bind to ICAM-1 in the presence 
and absence of PMA (Fig.  8). A  transfectant with a cyto- 
plasmic domain truncation mutation which has previously 
been shown to be defective in ICAM-1 binding (P2+ BD731"; 
reference  12), was used as a negative control. It shows no 
basal or stimulated binding to ICAM-1. B ceUs stably ex- 
pressing the point mutant 8S756C, which was not phos- 
phorylated in response to PMA, were both able to bind to 
ICAM-1 and to be stimulated in the presence of PMA (Fig. 
8). The amount of stimulated binding was equivalent to wild 
type. Unstimulated B cells expressing mutants to each of the 
three Thr residues consistently bound to ICAM-1 to lower 
levds than cells expressing wild-type LFA-1. ICAM-1 binding 
in the absence of PMA was reduced to "~20%  of normal. 
However, binding to ICAM-1 was still greatly enhanced by 
PMA in each of the three mutants. Thus, although phos- 
phorylation of 8 subunit threonine is found after PMA stim- 
ulation, phosphorylation of a specific threonine residue is not 
required for enhanced avidity of LFA-1. Furthermore, although 
mutants 8S756C and 8T758A are incapable of being phos- 
phorylated in response to PMA, their binding to ICAM-1 
is still stimulated by PMA. This demonstrates that phosphory- 
lation of the 8  subunit can be dissociated from the change 
in avidity of LFA-1 for ICAM-1 in response to PMA. B cells 
stably expressing 8 subunit mutations in the other potential 
phosphorylation sites in the cytoplasmic domain behaved like 
cells transfected with the wild-type 8 subunit; the cells could 
bind to ICAM-1, and their adhesive capacity was enhanced 
in the presence of PMA. 
Discussion 
We have identified key amino acids in two COOH-terminal 
regions of the cytoplasmic domain of the B subunit of the 
82 integrin LFA-1 that are important for adhesiveness. These 
residues are F766, which occurs four amino acids from the 
COOH terminus of the 8 subunit, and a string of three threo- 
nines, T758-760.  Since activation of adhesiveness is not a 
unique property of the 82 integrins, and has been reported 
for the 81 and 83 integrins as well (reviewed in reference 
1), the structural features we have defined may have broader 
relevance. The cytoplasmic domains of the 81, B2, and/33 
integrin subunits are highly homologous in the regions we 
have defined as important in avidity regulation (Fig. 9). The 
86 and 87 subunits, and less so the 85 subunit, and not the 
84 subunit, are also closely related in this region. Phenylala- 
nine 766 in the integrin 82 cytoplasmic domain is conserved 
as phenylalanine or tyrosine in 81, 83, 86, and 87. This corre- 
lates with our observation that substitution with tyrosine 
resulted in retention of binding to ICAM-1, whereas non- 
conservative  substitutions were deleterious.  The other four 
residues in the COOH-terminal segment could be deleted 
or substituted without affecting binding to ICAM-1; these 
are not conserved in the two other integrins that are known 
to undergo avidity regulation, 81 and 83. The three contig- 
uous  threonines  required  for  binding  to  ICAM-1  show 
similarity to motifs in other integrin 8 subunits. They align 
with  two contiguous threonines in 81,  threonine-serine- 
threonine in 83 and 85, three contiguous threonines in 87 
that are displaced one residue COOH terminally, and serine- 
threonine in 85. Thus, the sequence motifs we have defined 
that are important for the adhesiveness of the 82 integrins 
may also participate in regulation of adhesiveness of the 81, 
83, 86, and 87 integrins. The 84 cytoplasmic domain is most 
distinctive in sequence and also in cytoplasmic associations; 
it localizes to hemidesmosomes and thus associates with the 
keratin cytoskeleton (27,  28). 
Observations that the 8  subunit of LFA-1, Mac-l,  and 
p150,95 is phosphorylated in response to PMA, whereas the 
LFA-1, Mac-l, and p150,95 a  subunits are constitutively phos- 
phorylated (8,  10, 11), has led to speculation (8, 9), which 
we have tested, that phosphorylation  of the 8 subunit is respon- 
sible for the increased avidity of integrins on stimulated cells. 
The first step was to identify the phosphorylation site(s). Mu- 
tation of all the potential phosphorylation sites in the cyto- 
1233  Hibbs et al. Figure 7.  Identification of the phosphorylation sites 
in the/3 subunit cytophsmic domain using stably trans- 
fected B  lymphoblastoid cells expressing mutant/3 
subunits.  (A) Phosphoamino acid analysis of the B 
subunit immunopredpitated from LAD patient B lym- 
phoblastoid cells  transfected  with  the wild-type/3 
subunit and treated with 125 ng/ml PMA. (/3) Au- 
toradiograph  of 3zP-hbeled LFA-1 immunopreeipitated 
from LAD B lymphoblastoid  cells transfected with ei- 
ther the wild-type/3 subunit, or/3S756C. Cells were 
either treated with medium alone '-" or with  125 
ng/ml PMA "+" before lysis and immunoprecipita- 
tion. (C) Scanning densitometry of the 3 subunit im- 
munoprecipitated from LAD B lymphoblastoid cells 
transfected with either the wild-type/3 subunit or the 
designated mutant B subunit. Phosphorylation of the 
/3 subunit is presented as a percent of the phosphory- 
lation of the c~ subunit in the same immunoprecipi- 
tate;  phosphorylation of cx did not vary with PMA 
or/3 subunit mutation, as described  for COS cells. 
plasmic domain of the/3 subunit together with the phos- 
phoamino acid  analysis of the/3  subunit from wild-type 
PMA-stimulated cells allowed us to identify serine 756 as the 
major residue in the/3 subunit that is phosphorylated in re- 
sponse to PMA. Our phosphoamino acid analysis agrees with 
previous studies that have shown that serine is the principal 
phosphorylated residue (8, 10, 11). While the most obvious 
protein kinase responsible for PMA-induced phosphorylation 
is protein kinase C, the sequence surrounding serine 756 would 
not be predicted to be a good potential protein kinase C phos- 
phorylation site (29). This site may be an exceedingly poor 
substrate for protein kinase C, phosphorylated only under 
the influence of the potent activator PMA, or it may be phos- 
phorylated by a second protein kinase that is activated by pro- 
tein kinase C. Phosphorylation on serines homologous with 
serine 756 is predicted in/31 and/37 based on conservation 
of this serine and flanking sequences (Fig.  9).  Indeed, this 
serine must be phosphorylated in/31 because phosphoserine 
is present on 131 isolated from transformed cells (30) and there 
are no other serines in the B1 cytoplasmic domain (31). The 
/31 subunit tyrosine that is phosphoryhted  in cells transformed 
by tyrosine kinase oncogenes is just two residues NH2 ter- 
minal to the serine phosphorylation site (Y788;  Fig.  9); it 
is conserved as a tyrosine in most fl subunits but is a phenylala- 
nine in B2. 35 has been shown to be phosphorylated in re- 
sponse to phorbol ester in vivo and by protein kinase C in 
vitro (32). This must be at a different site because serine 756 
is not conserved in/35; two serines flanked with basic residues 
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Figure 8.  Binding of B lymphoblastoid  cells derived 
from patient 2 (P2) stably transfected with the indicated 
subunit mutants in the absence or presence of PMA 
to ICAM-l-coated plastic. Binding was performed in the 
presence of anti-HLA-A,  B  (control)  or anti-ICAM-1 
(RR1/1). Results are expressed as mean +_ SE. This ex- 
periment represents an average of two independent trials. 
Binding  was normalized in the two experiments as a per- 
cent of P2  +  B binding after PMA stimulation, which 
was 27% and 91% of input cells, respectively. 
in protein kinase C  recognition motifs (29, 33) are found 
14 and 17 residues in the NH2-terminal direction in B5 (34, 
35) and are not present in other integrin ~  subunits. 
We have identified residues that influence phosphorylation 
of serine 756, presumably by forming part of the kinase rec- 
ognition site or contributing to its conformation. The dele- 
tion L726AK755 abolishes PMA-stimulated phosphorylation, 
showing that residues NHz terminal to lysine 755 are im- 
portant for phosphorylation of serine 756. On the COOH- 
terminal side, threonine 758 but not threonine 760 contributed 
to PMA-stimulated phosphorylation. Although threonine was 
identified as a substrate in the phosphoamino acid analysis, 
the reduction in phosphorylation in mutant flT758A cannot 
be accounted for by the loss of this minor amount of phos- 
phothreonine. The loss of phosphorylation in this mutant 
is most easily explained by a change in the kinase binding 
site that affects phosphorylation at Ser756. 
82  754  FIK  S A  .TT  T  VlMIN  e K IA[]S 
788 
771  v Kgf A  T  V.  O  T  i  vl.  s  A,vlv  v  v,vj.  p KIVE  G. 
751  YRKP  I  SITiHTV  OF  T  F  NK  +10 
762  y  R G S[-~SITIF  KI-fflV T  Y K H R  +11 
87  777  YIKS  A]IIT  TIT  IIN-~Ri-F-]QI-ffiA  +5 
84  765  REN  L  MASDH  L  DT  PMLR  +972 
Figure 9.  Alignment  of the COOH-terminal region of the/~2 integrin 
cytoplasmic domain with other integrin B subunits. Amino acid substitu- 
tion or deletion mutations that reduce binding to ICAM-1 are overlined. 
The PMA-stimuhted phosphorylation site is asterisked. For ~5, the spacing 
between the threonine-rich  sequence and the phenylalanine is the same 
as for 81-3 and 86-7, but is shifted  +1. The number of the beginning 
residue, and number of COOH-terminal residues not shown, are indi- 
cated. Numbering  for B1 is for the chicken sequence; the human sequence 
is identical in the region shown but the corresponding  number is 783. 
Sequence references: B2 (43), B1 (31, 44), B3 (45), B5 (34, 35), B6 (46), 
~7 (47), and B4 (48, 49). 
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If the LFA-1 avidity  change were regulated through 
subunit phosphorylation, then no increase in LFA-1 adhe- 
siveness should be observed by a mutant that is incapable of 
being phosphorylated in response to PMA. However, mu- 
tants, in which the PMA-stimulated phosphorylation site at 
serine 756 as well as all other potential phosphorylation sites 
were substituted,  were capable of a dramatic increase in 
ICAM-1 binding in response to PMA. These findings dem- 
onstrate that phosphorylation of the ~ subunit on the major 
site at serine 756 can be dissociated from the increase in the 
avidity of  LFA-1 for ICAM-L Further evidence against regu- 
lation of avidity by phosphorylation of $756 comes from 
studies using LFA-1 expressed in COS cells. LFA-1 expressed 
in COS cells is in a constitutively active state as PMA cannot 
stimulate additional ICAM-1 binding (21); however, we have 
demonstrated that PMA can induce a substantial increase in 
subunit phosphorylation in COS cells. Furthermore, the 
deletion mutant BL726AK755 binds to ICAM-1 identically 
to wild type, yet shows no PMA-stimulated  phosphoryla- 
tion. The three contiguous threonines  are the only threo- 
nines present in the cytoplasmic domain, and it is intriguing 
that at least one of them is phosphorylated and that the threo- 
nines constitute a site important for activity of the extracel- 
lular domain in binding to ICAM-1. Although mutation of 
any one of these residues permitted increased avidity stimu- 
lated by PMA, both the basal- and PMA-stimulated binding 
were lower than for the wild-type ~ subunit, and it remains 
possible that phosphorylation of these residues is important 
in the function of LFA-1. 
We have identified two sites located close to the COOH- 
terminus of the ~ subunit that are important for maintaining 
the adhesive nature of LFA-1. The role of the amino acids 
in these regions in maintenance and regulation of the adhe- 
sive states of LFA-1 is not yet understood. These sites may 
form part of a contact site for another protein, possibly a 
cytoskeletal  protein,  that  is  involved  in  maintaining  or regulating LFA-1 avidity. Alternatively,  if aggregation of LFA-1 
molecules induces the increase  in avidity, these regions may 
be important for this self-association. We have thus far been 
unable to identify other proteins that coprecipitate with LFA-1. 
However, peptides based on the regions we have defined can 
now be synthesized to search for lower affinity interactions 
that have the same structure-activity relationships as defined 
by our mutational analysis. Cytoplasmic proteins that interact 
with the cadherin family of adhesion receptors have recently 
been defined. Cadherin adhesiveness is regulated through the 
cytoplasmic  domain  (36).  Cytoplasmic  proteins  termed 
catenins  have been shown to coprecipitate with  the deter- 
gent soluble fraction of cadherins. Deletions in the COOH- 
terminal half of the cytoplasmic domain of cadherins  not only 
abolish adhesiveness,  but association with the catenins (37, 
38). Truncation  of the cytoplasmic domain of the chicken 
31 integrin abrogates its ability to concentrate to focal con- 
tacts, areas of close apposition between cells and substrates 
(13-15). The cytoskeletal proteins talin, vinculin,  and c~-actinin 
localize in close association with integrins in focal contacts 
(39). None of these proteins have been demonstrated to as- 
sociate with integrins in vivo by techniques such as immu- 
noprecipitation, but evidence for an association between the 
cytoplasmic domain of the integrin ~1 subunit and both talin 
(40) and oz-actinin (41) has been obtained using purified pro- 
teins in vitro. Phosphorylation of Tyr788 of the B1 subunit 
has been suggested to decrease interaction  with talin (42), 
although subsequent mutagenesis of this residue has shown 
no effect on association with focal contacts (14). This residue 
is homologous to Phe754 orB2, which can be deleted without 
effect on adhesion to ICAM-1. A peptide found to compete 
integrin B1 binding to talin (42) is homologous to residues 
747 to 756 of B2, which is NH2 terminal to the function- 
ally important region we have defined. Thus, the present study 
focuses attention on two previously unappreciated sites in the 
COOH-terminal  one-third of integrin  B subunits that  are 
important for ligand binding by the extracellular domain of 
integrins.  It will be interesting to determine whether previ- 
ously defined cytoskeletal components,  or novel, as yet un- 
defined cytoplasmic proteins  interact  with  these sites. 
We thank Mr. J. Ventura for outstanding  technical assistance, Ms. E. Landsiedel for synthesis of oligonu- 
cleotides, Mr. E. Luther for flow cytometric analysis of transfectants, and Dr. R. Rothlein for mAb R15.7. 
This work was supported by National  Institutes  of Health  grant  37198 and by Boehringer  Ingelheim. 
M. L. Hibbs was supported by a grant from the Jane Cof~n Childs Memorial Fund for Medical Research. 
Address correspondence to TLmothy Springer, The Center for Blood Research and Department of Pathology, 
Harvard Medical School, 800 Huntington Avenue, Boston,  MA 02115. 
Received for publication  17 June  1991. 
P~ef'erences 
1.  Springer, T.A. 1990. Adhesion receptors of the immune system. 
Nature (Lond.). 346:425. 
2.  Rothlein,  R., M.L. Dustin, S.D. Marlin, and T.A. Springer. 
1986. A human intercellular adhesion molecule (ICAM-1) dis- 
tinct from LFA-1. J. Immunol.  137:1270. 
3.  Marlin, S.D., and T.A. Springer. 1987. Purified intercellular 
adhesion molecule-1 (ICAM-1)  is  a ligand  for lymphocyte 
function-associated antigen  1 (LFA-1). Cell. 51:813. 
4.  Staunton, D.E., M.L. Dustin, and T.A. Springer. 1989. Func- 
tional cloning of ICAM-2,  a cell adhesion ligand for LFA-1 
homologous  to ICAM-1. Nature (Lond.). 339:61. 
5.  de Fougerolles, A.R., S.A. Stacker, R. Schwarting, and T.A. 
Springer. 1991. Characterization  of ICAM-2 and evidence for 
a third  counter-receptor  for LFA-1. J. ExI~ Med.  174:253. 
6.  Dustin,  M.L., and T.A. Springer. 1989. T cell receptor cross- 
linking transiently stimulates adhesiveness through LFA-1. Na- 
ture (Lond.). 341:619. 
7.  van Kooyk, Y., P. van de Wiel-van Kemenade, P. Weder, T.W. 
Kuijpers, and  C.G.  Figdor.  1989. Enhancement  of LFA-1- 
mediated cell adhesion by triggering  through CD2 or CD3 
on T lymphocytes. Nature (Lond.). 342:811. 
8.  Chatila, T., R.S. Geha, and M.A. Arnaout.  1989. Constitu- 
tive and stimulus induced phosphorylation of CD11/CD18 leu- 
kocyte adhesion molecules. J. Cell Biol. 109:3435. 
9.  Figdor, C.G., Y. van Kooyk, and G.D. Keizer. 1990. On the 
mode of action of LFA-1. Immunol.  Today. 11:277. 
10.  Hara, T., and S.M. Fu.  1986. Phosphorylation  of alpha,beta 
subunits of 180/100-Kd polypeptides (LFA-1) and related an- 
tigens. In Leukocyte Typing II. Vol.3. Human Myeloid and 
Hematopoietic Cells. E.L. Reinherz,  B.F. Haynes, L.M. Na- 
dler, and I.D. Bernstein, editors. Springer-Verlag, New York. 
77-84. 
11.  Buyon, J.P.,  S.G. Slade, J. Reibman,  S.B, Abramson,  M.R. 
Philips, G. Weissman, and R. Winchester. 1990. Constitutive 
and induced phosphorylation  of the alpha- and beta-chains of 
the CDll/CD18 leukocyte integrin family.J. Immunol. 144:191. 
12.  Hibbs, M.L., H. Xu, S.A. Stacker, and T.A. Springer. 1991. 
Regulation of adhesion to ICAM-1 by the cytoplasmic domain 
of LFA-1 integrin beta subunit. Science (Wash. DC). 251:1611. 
13.  Solowska, J., J.L. Guan,  E.E. Marcantonio, J.E.  Trvithtick, 
C.A. Buck, and tk.O. Hynes. 1989. Expression of normal and 
mutant avian integrin  subunits  in rodent  cells. J.  Cell Biol. 
109:853. 
14.  Hayashi, Y., B. Haimovich, A. Reszka, D. Boettiger, and A. 
1236  Binding  Sites of Lymphokine Function-associated Antigen 1 Horwitz. 1990. Expression and function of chicken integrin 
beta1 subunit and its cytoplasmic domain mutants  in mouse 
NIH 3T3 cells. J. Cell Biol. 110:175. 
15.  Marcantonio, E.E., J, Guan, J.E. Trevithick, and R.O. Hynes. 
1990. Mapping of the functional determinants of the integrin 
beta-1 cytoplasmic domain by site-directed mutagenesis, Cell 
Reg. 1:597. 
16.  Barnstable, C.J., W.F. Bodmer, G. Brown, G. Galfre, C. Mil- 
stein, A.F. Williams, and A. Ziegler. 1978. Production ofmono- 
clonal antibodies to group A erythrocytes, HLA and other 
human  cell surface antigens: new tools for genetic analysis. 
Cell. 14:9. 
17.  Sanchez-Madrid, F., A.M.  Krensky, C.F. Ware, E. Robbins, 
J.L. Strominger, S.J. Burakoff, and T.A. Springer. 1982. Three 
distinct antigens associated with human  T lymphocyte-me- 
diated cytolysis: LFA-1, LFA-2, and LFA-3. Proc, Natl. Acad. 
Sci. USA.  79:7489. 
18.  Rothlein, R., M. Czajkowski, M.M. O'Neil, S.D. Marlin, E. 
Mainolfi, and V.J. Merluzzi.  1988. Induction of intercellular 
adhesion molecule 1 on primary and continuous cell lines by 
pro-inflammatory  cytokines.  Regulation  by pharmacologic 
agents and neutralizing  antibodies. J. Immunol.  141:1665. 
19.  Gluzman, Y. 1981. SV40-transformed simian cells support the 
replication of early SV40 mutants.  Cell. 23:175. 
20.  Hibbs, M.L., A.J. Wardlaw, S.A. Stacker, D.C. Anderson, A. 
Lee, T.M. Roberts,  and T.A. Springer. 1990. Transfection of 
cells from patients with leukocyte adhesion deficiency  with an 
integrin  beta subunit  (CD18) restores LFA-1 expression and 
function. J.  Clin. Invest. 85:674. 
21.  Larson, R.S., M.L. Hibbs, and T.A. Springer. 1990. The leu- 
kocyte integrin LFA-1 reconstituted by cDNA transfection in 
a nonhematopoietic cell line is functionally active and not tran- 
siently regulated.  Cell Reg. 1:359. 
22.  Seed,  B., and A. Aruffo. 1987. Molecular cloning of the CD2 
antigen, the T-cell  erythrocyte receptor, by a rapid immunoselec- 
tion procedure. Proc. Natl. Acad. Sci. USA.  84:3365. 
23.  Anderson, D.C., F.C. Schmalstieg, M.J. Finegold, B.J. Hughes, 
R. Rothlein, L.J. Miller, S. Kohl, M.F. Tosi, R.L. Jacobs, T.C. 
Waldrop, A.S. Goldman, W7I'. Shearer, and T.A. Springer. 1985. 
The severe  and moderate phenotypes of  heritable Mac-l, LFA-1 
deficiency:  Their quantitative definition and relation to leuko- 
cyte dysfunction and clinical features. J. Infect. l~'s. 152:668. 
24.  Kunkel, T.A. 1985. Rapid and efficient site-specific  mutagen- 
esis without phenotypic selection. Proc. Natl. Acad. Sci. USA. 
82:488. 
25.  Laemmli, U.K.  1970. Cleavage of structural proteins during 
the assembly of the head of bacteriophage T4. Nature (Lond.). 
227:680. 
26.  Wardlaw, A.J., M.L. Hibbs, S.A. Stacker, and T.A. Springer. 
1990. Distinct mutations in two patients with leukocyte adhe- 
sion deficiency and their functional correlates. J. Exp. Med. 
172:335. 
27.  Stepp, M.A., S. Spurr-Michaud, A. Tisdale,  J. Elwell, and I.K. 
Gipson. 1990. Alpha 6 beta 4 integrin heterodimer is a com- 
ponent ofhemidesmosomes.  Proa Natl..A_cad. Sci. USA. 87:8970. 
28.  Carter, W.G., P. Kanr, S.G. Gil, p.J. Gahr, and E.A. Wayner. 
1990. Distinct  functions for integrins alpha 3 beta 1 in focal 
adhesions and alpha 6 beta 4/bullous pemphigoid antigen in 
a new stable anchoring contact (SAC) of keratinocytes: rela- 
tion to hemidesmosomes. J.  Cell Biol. 111:3141. (Abstr.) 
29.  House, C.,  R.E.H. Wettenhall,  and B.E. Kemp. 1987. The 
influence of basic residues on the substrate specificity of pro- 
tein kinase C. f  Biol. Chem. 262:772. 
30.  Hirst, R., A. Horwitz, C. Buck, and L. Rohrschneider. 1986. 
Phosphorylation of the fibronectin receptor complex in cells 
transformed by oncogenes that encode tyrosine kinases. Pro~ 
Natl. Acad. Sci. USA.  83:6470. 
31.  Tamkum, J.W.,  D.W. DeSimone, D.  Fonda, R.S.  Patel, C. 
Buck, A.F. Horwitz, and R.O. Hynes. 1986. Structure ofinte- 
grin,  a glycoprotein involved in the transmembrane linkage 
between fibrunectin and actin. Cell. 46:271. 
32.  Freed, E., J. Gailit, P. van der Geer, E. Ruoslahti, and T. Hunter. 
1989. A novel integrin  beta subunit  is associated with the 
vitronectin receptor alpha subunit in a human osteosarcoma 
cell line and is a substrate for protein kinase C. EMBO (Eur. 
Mol. Biol. Organ.)  f  8:2955. 
33.  Kemp, B.E., and R.B. Pearson. 1990. Protein kinase recogni- 
tion sequence motifs.  Trends Biol. Sci. 15:342. 
34.  Ramaswamy, H., and M.E. Hemler. 1990. Cloning, primary 
structure and properties of  a novel  human integrin beta subunit. 
EMBO (Fur. Mol. Biol. Organ.).]. 9:1561. 
35.  McLean, J.W., D.J. Vestal, D.A.  Cheresh, and S.C. Bodary. 
1990. cDNA sequence of the human integrin beta 5 subunit. 
J. Biol. Chem. 265:17126. 
36.  Takeichi, M.  1990. Cadherins: a molecular family important 
in selective cell-cell adhesion. Annu,  Rev. Biochem. 59:237. 
37.  Nagafuchi, A., and M. Takeichi. 1989. Transmembrane con- 
trol of cadherin-mediated cell adhesion: a 94 kDa protein func- 
tionally associated with a specific region of the cytoplasmic 
domain of E-cadherin. Cell Reg. 1:37. 
38.  Ozawa, M., M. Ringwald, and R. Kemler. 1990. Uvomorulin- 
catenin complex formation is regulated by a specific domain 
in the cytoplasmic region of the cell adhesion molecule. Proc. 
Natl.  Acad. Sci. USA.  87:4246. 
39.  Burridge, K., K. Fath, T. Kelly, G. Nuckolls, and C. Turner. 
1988. Focal Adhesions: Transmembranejunctions between the 
extracellular matrix and the cytoskeleton. Annu. Rev. Cell Biol. 
4:487. 
40.  Horwitz, A., K. Duggan, C. Buck, M.C. Beckerle, and K. 
Burridge. 1986. Interaction of plasma membrane fibronectin 
receptor with talin: a transmembrane linkage. Nature (Lond.). 
320:531. 
41.  Otey, C.A., F.M. Pavalko, and K. Burridge. 1990. An interac- 
tion between  alpha-actinin and  the t31 integrin  subunit  in 
vitro, j.  Cell Biol. 111:721. 
42.  Tapley,  P., A. Horwitz, C. Buck, K. Duggan, and L. Rohr- 
schneider. 1989. Integrins isolated from Rous sarcoma virus- 
transformed chicken embryo fibroblasts. Oncogene. 4:325. 
43.  Kishimoto, T.K., N. Hollander, T.M. Roberts, D.C. Anderson, 
and T.A. Springer. 1987. Heterogenous mutations in the beta 
subunit common to the LFA-1, Mac-l, and p150,95 glycopro- 
teins cause leukocyte adhesion deficiency. Cell. 50:193. 
44.  Argraves, W.S., S.  Suzuki,  H.  Arai, K.  Thompson, M.D. 
Pierschbacher, and E. Ruoslahti.  1987. Amino acid sequence 
of the human  fibronectin receptor. J.  Cell Biol. 105:1183. 
45.  Fitzgerald, L.A., 13. Steiner, S. C. Rail, Jr., S. Lo, and D.R. 
Phillips. 1987. Protein sequence  of  endothelial glycoprotein IIIa 
derived from a cDNA clone. Identity with platelet glycopro- 
tein IIIa and similarity to "integrin"J. Biol. Chem. 262:3936. 
46.  Sheppard, D., C. Rozzo, L. Starr, V. Quaranta, D.J. Erie, and 
R. Pytela. 1990. Complete amino acid sequence  of  a novel inte- 
grin ~/subunit (~6) identified in epithelial cells using the poly- 
merase chain reaction. J. Biol. Chem. 265:11502. 
47.  Yuan, Q., W.-M. Jiang, G.W. Krissansen, and J.D. Watson. 
1237  Hibbs  et al. 1990. Cloning and sequence analysis of a novel beta 2-related 
integrin  transcript  from T lymphocytes: homology of inte- 
grin cysteine-rich repeats to domain III of laminin B chains. 
Int.  lmmunol.  2:1097. 
48.  Hogervorst, F., I. Kuikman, A.E.G.K. Von dem Borne, and 
A. Sonnenberg. 1990. Cloning and sequence analysis of  beta-4 
cDNA: an integrin subunit that contains a unique 118 kd cy- 
toplasmic domain. EMBO (Eur. Mol. Biol. Organ.) J.  9:765. 
49.  Suzuki, S., and Y. Naitoh. 1990. Amino acid sequence of a 
novel integrin beta 4 subunit and primary expression of the 
mRNA in epithelial cells. EMBO (Eur. Mol. Biol. Organ.)J. 
9:757. 
1238  Binding  Sites of Lymphokine Function-associated  Antigen 1 